MIM
ANRO icon

MetLife Investment Management’s Alto Neuroscience ANRO Stock Holding History

MetLife Investment Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,783
Closed -$146K – 2866
2024
Q3 		$146K Buy
+12,783
New +$156K ﹤0.01% 2450

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

MetLife Investment Management's ANRO Position: Q4 2024 in Review

MetLife Investment Management sold out of Alto Neuroscience (ANRO) in Q4 2024, closing a stake of 12,783 shares — an estimated $146K sold.

MetLife Investment Management first reported a position in ANRO in Q3 2024 and held it in 1 quarter. The position peaked at $146K in Q3 2024. 77 funds tracked by Wall St. Rank hold ANRO as of Q4 2024.

  • MetLife Investment Management reported no remaining Alto Neuroscience position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 12,783 Alto Neuroscience shares in Q4 2024, an estimated $146K.
  • MetLife Investment Management first reported a position in Alto Neuroscience in Q3 2024 and held it in 1 quarter.
  • MetLife Investment Management's Alto Neuroscience position peaked at $146K in Q3 2024.
  • 77 funds tracked by Wall St. Rank held Alto Neuroscience as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.